Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Febantel
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Febantel is a veterinary anthelmintic drug belonging to the benzimidazole class, primarily used to treat gastrointestinal nematode infections in animals, especially dogs. It acts as a pro-drug that is metabolized in the liver to form fenbendazole and other active metabolites. The mechanism of action involves interference with microtubule formation in parasitic cells, inhibition of glucose uptake, and disruption of energy metabolism within parasites. Febantel is commonly included as one component in combination deworming products (such as Drontal Plus) for broad-spectrum control of roundworms, hookworms, whipworms, and tapeworms[3][6]. It is not recommended for use in pregnant animals or very young puppies[5].
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Febantel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Febantel.